Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagida Bibi

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
Nature Communications|October 7, 2021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in BrazilSue Ann Costa Clemens, Pedro M Folegatti, Katherine R W Emary, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|July 21, 2025
Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in BrazilSue Ann Costa Clemens, Sagida Bibi, Natalie G Marchevsky, et al.
Lancet (London, England)|July 24, 2020
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialPedro M Folegatti, Katie J Ewer, Parvinder K Aley, et al.
Lancet (London, England)|January 25, 2022
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised studySue Ann Costa Clemens, Lily Weckx, Ralf Clemens, et al.
Cell|June 30, 2022
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serumAekkachai Tuekprakhon, Rungtiwa Nutalai, Aiste Dijokaite-Guraliuc, et al.
Cell|June 6, 2022
Potent cross-reactive antibodies following Omicron breakthrough in vaccineesRungtiwa Nutalai, Daming Zhou, Aekkachai Tuekprakhon, et al.
Lancet (London, England)|September 4, 2021
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)Amy Flaxman, Natalie G Marchevsky, Daniel Jenkin, et al.
Clinical and Experimental Immunology|February 2, 2023
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trialsMerryn Voysey, Amy Flaxman, Jeremy Aboagye, et al.
Science Immunology|August 29, 2025
MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccinesAli Amini, Lucy C Garner, Robert H Shaw, et al.
Cell Reports|December 31, 2022
A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75Jiandong Huo, Aiste Dijokaite-Guraliuc, Chang Liu, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Nature Communications|October 7, 2021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in BrazilSue Ann Costa Clemens, Pedro M Folegatti, Katherine R W Emary, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|July 21, 2025
Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in BrazilSue Ann Costa Clemens, Sagida Bibi, Natalie G Marchevsky, et al.
Lancet (London, England)|July 24, 2020
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialPedro M Folegatti, Katie J Ewer, Parvinder K Aley, et al.
Lancet (London, England)|January 25, 2022
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised studySue Ann Costa Clemens, Lily Weckx, Ralf Clemens, et al.
Cell|June 30, 2022
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serumAekkachai Tuekprakhon, Rungtiwa Nutalai, Aiste Dijokaite-Guraliuc, et al.
Cell|June 6, 2022
Potent cross-reactive antibodies following Omicron breakthrough in vaccineesRungtiwa Nutalai, Daming Zhou, Aekkachai Tuekprakhon, et al.
Lancet (London, England)|September 4, 2021
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)Amy Flaxman, Natalie G Marchevsky, Daniel Jenkin, et al.
Clinical and Experimental Immunology|February 2, 2023
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trialsMerryn Voysey, Amy Flaxman, Jeremy Aboagye, et al.
Science Immunology|August 29, 2025
MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccinesAli Amini, Lucy C Garner, Robert H Shaw, et al.
Cell Reports|December 31, 2022
A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75Jiandong Huo, Aiste Dijokaite-Guraliuc, Chang Liu, et al.
Pageof 6